# LMCD1

## Overview
LMCD1 (LIM and cysteine-rich domains 1) is a gene that encodes a multifunctional protein involved in various cellular processes, particularly in skeletal muscle, bone marrow stem cells, and testicular function. The LMCD1 protein is characterized by its LIM and cysteine-rich domains, which are zinc-binding motifs that facilitate protein-protein interactions, categorizing it as a regulatory protein (wang2005cdna; Ferreira2019LIM). In skeletal muscle, LMCD1 plays a pivotal role in regulating muscle hypertrophy and calcium handling, primarily through its interaction with calcineurin, which influences muscle performance and fatigue resistance (Ferreira2019LIM). Additionally, LMCD1 is crucial for osteogenic differentiation in bone marrow stem cells by modulating bone morphogenetic protein (BMP) signaling, thereby promoting bone formation and maintaining bone homeostasis (Zhu2019LMCD1). The protein also contributes to testicular function by regulating phagocytosis in Sertoli cells, essential for male fertility (Jin2020Testicular). LMCD1's involvement in these diverse biological processes underscores its significance in both normal physiology and disease states, including its potential role as a marker in prostate cancer and its implication in hepatocellular carcinoma (Chang2011Somatic; Dmitriev2015Identification).

## Structure
The LMCD1 protein is composed of 363 amino acids and has a molecular weight of approximately 40,788 Da with an isoelectric point (pI) of 8.39 (wang2005cdna). Its primary structure includes a novel cysteine-rich domain located in the N-terminal region and two LIM domains in the C-terminal region, which are zinc-binding motifs crucial for protein-protein interactions (wang2005cdna; Ferreira2019LIM). These domains suggest a role in skeletal muscle protein interactions and regulation (wang2005cdna).

The protein undergoes several post-translational modifications, including phosphorylation at multiple sites: nine potential protein kinase C phosphorylation sites, seven casein kinase II phosphorylation sites, and a tyrosine kinase phosphorylation site. It also has seven N-glycosylation and N-myristoylation sites, along with a single potential N-glycosylation site (wang2005cdna). These modifications likely influence the protein's activity and interactions.

LMCD1 is involved in regulating muscle hypertrophy and calcium handling, with its actions dependent on calcineurin signaling. It interacts with calcineurin to modulate muscle performance and fatigue resistance (Ferreira2019LIM). The protein's structure and modifications are integral to its function in muscle physiology.

## Function
LMCD1 (LIM and cysteine-rich domains 1) is a gene that encodes a protein involved in various cellular processes, particularly in skeletal muscle and bone marrow stem cells. In skeletal muscle, LMCD1 plays a crucial role in regulating muscle hypertrophy, calcium handling, and force production. It enhances protein synthesis and muscle fiber size, leading to increased muscle mass and specific force. LMCD1 achieves this by interacting with calcineurin to modulate myoregulin (MLN) expression, which in turn affects calcium dynamics and muscle performance (Ferreira2019LIM).

In bone marrow stem cells, LMCD1 is essential for osteogenic differentiation by regulating bone morphogenetic protein (BMP) signaling. It stabilizes key proteins like RUNX2 and Smad1 by reducing their ubiquitination, thereby promoting bone formation and inhibiting adipogenic differentiation. This regulation is critical for maintaining bone homeostasis and ensuring proper osteogenic commitment of stem cells (Zhu2019LMCD1).

LMCD1 is also involved in testicular function, particularly in Sertoli cells, where it regulates phagocytosis through the NFAT1/Txlna signaling pathway. This process is vital for maintaining testicular homeostasis and male fertility (Jin2020Testicular).

## Clinical Significance
LMCD1 has been implicated in several diseases due to mutations and alterations in its expression. In prostate cancer, LMCD1 is frequently methylated, particularly in aggressive cases, suggesting its potential as a marker for aggressive prostate cancer. Methylation or deletion of LMCD1, along with other markers, can indicate aggressive disease with high sensitivity and specificity (Dmitriev2015Identification).

In hepatocellular carcinoma (HCC), LMCD1 is identified as a candidate oncogene. Mutations such as E135K and K237R in LMCD1 are associated with increased cell migration and tumor metastasis. These mutations enhance Rac1 signaling, leading to lamellipodia formation and systemic tumor metastasis, particularly in the case of the E135K mutation (Chang2011Somatic).

LMCD1 also plays a role in skeletal muscle function. Its expression decreases in conditions like Duchenne muscular dystrophy and aging, while overexpression induces muscle hypertrophy and enhances muscle force. Silencing LMCD1 impairs calcium handling and decreases muscle force, indicating its importance in muscle function and potential involvement in muscle diseases (Ferreira2019LIM).

Additionally, LMCD1 is involved in osteogenic differentiation. Alterations in its expression affect bone formation by modulating BMP signaling, impacting the stability of proteins like RUNX2 and Smad1, which are crucial for bone development (Zhu2019LMCD1).

## Interactions
LMCD1, or LIM and cysteine-rich domains 1, is known to participate in various protein-protein interactions that influence cellular processes. One significant interaction is with the transcription factor GATA6. LMCD1 acts as a transcriptional cofactor that inhibits GATA6 function by preventing its DNA binding. This interaction is mediated through the LIM and CYS domains of GATA6, with the carboxy-terminal zinc finger of GATA6 playing a crucial role in this binding. LMCD1 also interacts with other GATA family members, such as GATA1 and GATA4, due to the conserved nature of the zinc finger domain (Rath2005LMCD1Dyxin).

In skeletal muscle, LMCD1 interacts with calcineurin to regulate muscle hypertrophy and calcium handling. This interaction is crucial for the repression of myoregulin (MLN), a negative regulator of muscle performance, thereby enhancing SERCA pump activity and improving calcium handling (Ferreira2019LIM). LMCD1 also influences the AKT/S6K signaling pathway, promoting protein synthesis and muscle fiber growth (Ferreira2019LIM).

In the context of osteogenic differentiation, LMCD1 interacts with the BMP signaling pathway by associating with RUNX2 and Smad1, reducing their ubiquitination degradation mediated by the E3 ligase Smurf1. This interaction is essential for the osteogenic differentiation of human bone marrow stem cells (Zhu2019LMCD1).


## References


1. (wang2005cdna) Jun Wang, Chang-Yan DENG, Yuan-Zhu XIONG, Bo Zuo, Lei Xing, Feng-E LI, Ming-Gang LEI, Rong Zheng, and Si-Wen JIANG. Cdna cloning, sequence analysis of the porcine lim and cysteine-rich domain 1 gene. Acta biochimica et biophysica Sinica, 37(12):843–850, 2005. This article has 7 citations and is from a peer-reviewed journal.

[2. (Zhu2019LMCD1) Bin Zhu, Feng Xue, Changqing Zhang, and Guangyi Li. Lmcd1 promotes osteogenic differentiation of human bone marrow stem cells by regulating bmp signaling. Cell Death &amp; Disease, September 2019. URL: http://dx.doi.org/10.1038/s41419-019-1876-7, doi:10.1038/s41419-019-1876-7. This article has 14 citations.](https://doi.org/10.1038/s41419-019-1876-7)

[3. (Rath2005LMCD1Dyxin) Nibedita Rath, Zhishan Wang, Min Min Lu, and Edward E. Morrisey. Lmcd1/dyxin is a novel transcriptional cofactor that restricts gata6 function by inhibiting dna binding. Molecular and Cellular Biology, 25(20):8864–8873, October 2005. URL: http://dx.doi.org/10.1128/mcb.25.20.8864-8873.2005, doi:10.1128/mcb.25.20.8864-8873.2005. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.25.20.8864-8873.2005)

[4. (Dmitriev2015Identification) Alexey A. Dmitriev, Eugenia E. Rosenberg, George S. Krasnov, Ganna V. Gerashchenko, Vasily V. Gordiyuk, Tatiana V. Pavlova, Anna V. Kudryavtseva, Artemy D. Beniaminov, Anastasia A. Belova, Yuriy N. Bondarenko, Rostislav O. Danilets, Alexander I. Glukhov, Aleksandr G. Kondratov, Andrey Alexeyenko, Boris Y. Alekseev, George Klein, Vera N. Senchenko, and Vladimir I. Kashuba. Identification of novel epigenetic markers of prostate cancer by noti-microarray analysis. Disease Markers, 2015:1–13, 2015. URL: http://dx.doi.org/10.1155/2015/241301, doi:10.1155/2015/241301. This article has 39 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2015/241301)

[5. (Chang2011Somatic) C-Y Chang, S-C Lin, W-H Su, C-M Ho, and Y-S Jou. Somatic lmcd1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene, 31(21):2640–2652, September 2011. URL: http://dx.doi.org/10.1038/onc.2011.440, doi:10.1038/onc.2011.440. This article has 31 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2011.440)

[6. (Jin2020Testicular) Xiaohang Jin, Sheng Zhang, Tianbing Ding, Pengtao Zhao, Chunli Zhang, Yuxing Zhang, and Wei Li. Testicular lmcd1 regulates phagocytosis by sertoli cells through modulation of nfat1/txlna signaling pathway. Aging Cell, August 2020. URL: http://dx.doi.org/10.1111/acel.13217, doi:10.1111/acel.13217. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/acel.13217)

[7. (Ferreira2019LIM) Duarte M. S. Ferreira, Arthur J. Cheng, Leandro Z. Agudelo, Igor Cervenka, Thomas Chaillou, Jorge C. Correia, Margareta Porsmyr-Palmertz, Manizheh Izadi, Alicia Hansson, Vicente Martínez-Redondo, Paula Valente-Silva, Amanda T. Pettersson-Klein, Jennifer L. Estall, Matthew M. Robinson, K. Sreekumaran Nair, Johanna T. Lanner, and Jorge L. Ruas. Lim and cysteine-rich domains 1 (lmcd1) regulates skeletal muscle hypertrophy, calcium handling, and force. Skeletal Muscle, October 2019. URL: http://dx.doi.org/10.1186/s13395-019-0214-1, doi:10.1186/s13395-019-0214-1. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13395-019-0214-1)